-
Streetinsider.com's Hot Lunchtime Reads 9/26: (REGN) (ONTX) (LITE) (SFL)
-
Roth Capital Reaffirms Regeneron (REGN) at 'Buy'; Dupilumab BLA in AD Key Next Step in Development
-
Roth Capital Reiterates Regeneron (REGN) at 'Buy' Following New Teva Pharma Ffasinumab Partnership
-
Notable Analyst Rating Changes 8/5: (SYMC) (COH) (OAS) Upgraded; (ICPT) (PKI) (REGN) Downgraded
-
Roth Keeps Regeneron (REGN) at 'Buy' Following Q2 Report; Says 'Blocking and Tackling' Continues
-
Roth Expects Full Approval of Regeneron (REGN) Dupilumab, Trims PT to $520
-
Roth Affirms Regeneron (REGN) at 'Buy' Following Q4 Results; Sees Opportunity in Shares on Pullback
-
Roth Capital Upgrades Regeneron Pharma (REGN) to Buy
-
Roth Capital Positive on Regeneron (REGN) Following 'Impressive' Deal with Sanofi (SNY)'; Affirms at 'Buy'
-
Regeneron (REGN) Investors Already Pricing-in Praluent Approval; Roth Capital Affirms at 'Neutral'
-
Notable Analyst Rating Changes 7/9: (TRV) (MBLY) (JBHT) Upgraded; (SHAK) (REGN) (VR) Downgraded
-
Roth Lifts PT on Regeneron (REGN) to $495 Following Sarilumab Phase 3 Results in RA
-
Roth Affirms Regeneron (REGN) at 'Neutral'; Dupilumab Success in Asthma Largely Priced-in
-
Regeneron Pharma (REGN) PT Lifted to $490 at Roth Capital
-
Notable Analyst Rating Changes 2/20: (MRVL) (DSW) (KN) Upgraded; (FUEL) (HLSS) (REGN) Downgraded
-
Roth Capital Downgrades Regeneron (REGN) to Neutral; Pipeline Opportunities Largely Priced In
-
Regeneron (REGN) Misses Q4 GAAP EPS Views on R&D, Pipeline Expansion, but EYLEA Shaping-Up Well - Roth Capital
-
Regeneron (REGN), Sanofi (SNY) on 'Last Stretch' of Praluent Development - Roth Capital
-
Regeneron's (REGN) Eylea sBLA Receives Priority Review as DME + Diabetic Retinopathy Treatment; Roth Capital Comments
-
Streetinsider.com's Hot Lunchtime Reads 11/20: (LB) (AMZN) (REGN) (GS) (FB)
-
Regeneron's (REGN) Dupilumab Receives FDA Breakthrough Designation; Roth Capital Comments
-
Roth Comments on Regeneron (REGN) Following ODYSSEY Update at AHA (SNY)
-
Roth Capital Remains Positive on Regeneron (REGN); Latest Outcome Better Positions Eylea as Superior DME Treatment
-
Roth Keeps Regeneron (REGN) at 'Buy'; Another Eylea Approval is No Surprise
-
Latest Data for Regeneron's (REGN) Dupilumab Broadens Benefit Profile - Roth
-
Roth Lifts Price Target on Regeneron (REGN) to $422 Following ODYSSEY Phase III Updates
-
Roth Capital Comments on Regeneron (REGN) After EC Approves Eylea for DME Patients
-
Roth Capital Comments on Regeneron (REGN) Following Q2 Results; Affirms 'Buy' Rating
-
Roth Boosts PT on Regeneron (REGN) to $399 Following ODYSSEY Phase III Data, EYLEA Approval
-
Roth Capital Affirms Regeneron (REGN) at 'Buy'; Comments on Eylea Phase III VIVID-DME Two-Year Data
-
Roth Capital Affirms Regeneron (REGN) at 'Buy' Following Positive Dupilumab Phase 2b Update
-
Roth Comments on Regeneron (REGN), Sanofi Presentation of Sarilumab Phase 3 Data; Affirms at 'Buy'
-
Roth Comments on Regeneron's (REGN) MAA Submission for EYLEA to EU; Reaffirms 'Buy' Rating
-
Roth Sees Regeneron/Sanofi Alirocumab Phase 2 Results as Positive; Maintains 'Buy' Rating (REGN)
-
Roth Raises PT on Regeneron (REGN) to $382; ODYSSEY MONO, Alirocumab Data Bolsters Positive Outlook
-
Regeneron Pharma (REGN) PT Raised to $382 at Roth Capital
-
Notable Analyst Rating Changes 02/13: (ANR) (ATHN) (NSPH) Upgraded; (DEPO) (REGN) (AEM) Downgraded
-
Roth Keeps Regeneron (REGN) at 'Buy' Following Q4 Numbers, Outlook; VISTA, OUTLOOK Still in Focus
-
Notable Analyst Rating Changes 02/12: (CROX) (S) (ZTS) Upgraded; (AMZN) (DF) (GMCR) Downgraded
-
Regeneron (REGN) Remains Strong Buy Following Recent Positive News - Roth Capital
-
Roth Capital Downgrades Regeneron Pharma (REGN) to Neutral
-
Roth Capital Upgrades Regeneron Pharma (REGN) to Buy
-
Notable Analyst Rating Changes 10/26: (AMTD) (NFLX) (REGN) Upgraded; (HGSI) (FSLR) (MF) Downgraded
-
Roth Capital Starts Regeneron Pharma (REGN) at Neutral
-
Regeneron (REGN) Shares Trade Up on FDA Alert on Avastin
-
Roth Capital Upgrades Regeneron Pharma (REGN) to Buy
-
Roth Capital Upgrades Regeneron Pharma (REGN) to Neutral
-
Roth Capital Initiates Coverage on Biotechnology and Drugs Stocks